Related Experiment Video
Updated: Jun 6, 2025
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a
Shuiqing Xu1, Wenming Chen2, Yanchen Li2
1Beijing Chaoyang Integrative Medicine Rescue and First Aid Hospital, Beijing, People's Republic of China.
Objective:
To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).
Methods:
The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups.
Results:
The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88, p = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01, p = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups, P = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27, P = 0.002).
Conclusions:
The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority.
Insights
Daratumumab-based regimens significantly improved overall survival (OS) and efficacy in newly diagnosed multiple myeloma (NDMM) patients with paraskeletal plasmacytomas (PPs). These findings support prioritizing daratumumab combinations for multiple myeloma patients with extramedullary disease (EMD).
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Multiple myeloma (MM) is a hematologic malignancy.
- Paraskeletal plasmacytomas (PPs) represent a form of extramedullary disease (EMD) in MM.
- Treatment strategies for NDMM with PPs require optimization.
Purpose of the Study:
- To evaluate the efficacy of daratumumab-based regimens in newly diagnosed multiple myeloma (NDMM) patients with paraskeletal plasmacytomas (PPs).
- To compare outcomes between daratumumab-based and daratumumab-free regimens in this patient cohort.
Main Methods:
- Retrospective analysis of 28 NDMM patients with PPs.
- Division of patients into two groups: daratumumab-based regimen (Group A) and daratumumab-free regimen (Group B).
- Comparison of risk factors, efficacy, and overall survival (OS) between the groups using COX regression analysis.
Main Results:
- Daratumumab-based regimens (Group A) showed a statistically significant improvement in efficacy (P=0.025).
- Group A demonstrated a significantly longer overall survival (OS) compared to Group B (54 months vs. 27 months, P=0.002).
- Daratumumab treatment was identified as a protective factor for patient survival (HR=0.30, P=0.029), while creatinine was a risk factor (HR=1.00, P=0.026).
Conclusions:
- Daratumumab-containing treatment regimens can significantly prolong OS in NDMM patients with PPs.
- Daratumumab-based combination therapies should be prioritized for multiple myeloma patients presenting with extramedullary disease (EMD).
- Further prospective studies are warranted to confirm these findings.
